Lineage Cell Therapeutics (LCTX) Free Cash Flow (2010 - 2026)

Lineage Cell Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 63.52% year-over-year to -$8.1 million; the trailing twelve-month figure through Mar 2026 stood at -$22.6 million (up 0.93% YoY), and the FY2025 full-year result was -$19.4 million, up 17.82% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$8.1 million, down from -$5.4 million in the prior quarter.
• The five-year high for Free Cash Flow was $21.9 million in Q1 2022, with the low at -$11.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$4.7 million across 5 years, with a median of -$5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 393.99% — and 2023, when it slumped 152.29%.
• Lineage Cell Therapeutics' Free Cash Flow stood at -$7.9 million in 2022, then grew by 15.4% to -$6.7 million in 2023, then decreased by 0.39% to -$6.7 million in 2024, then increased by 19.91% to -$5.4 million in 2025, then sank by 51.59% to -$8.1 million in 2026.
• The last three Free Cash Flow figures came in at -$8.1 million (Q1 2026), -$5.4 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.